The market for antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) is poised for significant growth, projected to surpass $3.9 billion by 2032 across the USA, Europe, and Japan, according to data and analytics group GlobalData.
This expansion follows a prolonged period of limited ADC presence in NSCLC. Although the American medicines regulator approved Pfizer’s (NYSE: PFE) Mylotarg (gemtuzumab ozogamicin) in 2000, it wasn't until 2022 that the first ADC for NSCLC—AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab deruxtecan)—received approval, targeting HER2-mutated tumors.
Since then, the development pipeline has accelerated. GlobalData anticipates a compound annual growth rate of 6.8% for ADCs in NSCLC across the seven major markets—USA, France, Germany, Italy, Spain, the UK, and Japan—driven by late-stage candidates nearing approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze